Human epidermal growth factor receptor 2 (HER2) immunoreactivity: Specificity of three pharmacodiagnostic antibodies

Histopathology

Volumn 59, Issue 5, 2011, Pages 975-983

  Schrohl, Anne Sofie ^a   Pedersen, Hans Christian ^b   Jensen, Sussie Steen ^b   Nielsen, Signe Lykke ^a   Brünner, Nils ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

Antibody specificity; HER2 protein; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 81555196461     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04034.x     Document Type: Article

References (16)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001; 2; 127-137.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244; 707-712.
3. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131; 18-43.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235; 177-182.
5. Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989; 49; 2087-2090.
6. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003; 200; 290-297.
7. Sassen A, Rochon J, Wild P et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008; 10; R2.
8. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004; 6; R246-R251.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344; 783-792.
10. Powell WC, Hicks DG, Prescott N et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 94-102.
11. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst. 2002; 94; 852-854.
12. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J. Clin. Oncol. 2006; 24; 3032-3038.
13. Mayr D, Heim S, Werhan C, Zeindl-Eberhart E, Kirchner T. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Arch. 2009; 454; 241-248.
14. Corbett IP, Henry JA, Angus B et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J. Pathol. 1990; 161; 15-25.
15. Geysen HM, Meloen RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl Acad. Sci. USA 1984; 81; 3998-4002.
16. Leica Microsystems GmbH. Oracle™ HER2 Bond™ IHC system interpretation guide. Mannheim, Germany: Leica Microsystems GmBH, 2009.